Stool and symptom testing in ColoREctal Evaluation for Neoplasia in Cystic Fibrosis (SCREEN-CF)
Journal of Cystic Fibrosis · 2026
DOI: 10.1016/j.jcf.2025.09.008 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Nicole A Taylor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, 2050, Australia; University of New South…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Colorectal Neoplasms, Feces, Early Detection of Cancer. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Foundation, National Health and Medical Research Council, Australian Cystic Fibrosis Research Trust.
Abstract (Originalsprache)
BACKGROUND: People with cystic fibrosis (pwCF) have increased colorectal cancer (CRC) risk. Colonoscopy is recommended, yet CF comorbidities increase complexity and risk. METHODS: We conducted a prospective, observational study of pwCF meeting colonoscopy screening guidelines at an Australian centre (2019 - 2023). Immunochemical faecal occult blood test (iFOBT), faecal calprotectin (FC), and faecal tumour pyruvate kinase isoenzyme type M2 (TuM2-PK) were evaluated for detecting adenomatous polyps and malignant ileocolonic lesions in pwCF. Stools were collected within 3 months of colonoscopy. Diagnostic performance and optimal cut-offs were calculated. RESULTS: Among 49 participants [mean (SD) age 47.8 (8.2) years; 53 % female], 12 (24.5 %) were post-solid organ transplant, 10 (20.4 %) had > 3 months of triple modulator therapy at stool testing, 12 (24.5 %) had adenomatous polyps and 2 (4 %) had ileocolonic malignancy. Malignancies were in non-transplanted individuals, in the terminal ileum (age 43) and hepatic flexure/ascending colon (age 48). Higher BMI (>23.5 kg/m²) was associated with abnormal colonoscopy (p = 0.03). iFOBT, FC and TuM2PK demonstrated excellent predictive performance for malignancy (AUC 0.93, 1.00, 0.83; all p < 0.05). Only FC had acceptable predictive performance for pre-malignant lesions (AUC 0.73; p = 0.008). For adenomatous polyps, FC ≤100 µg/g achieved a sensitivity of 91.7 % and an NPV of 95.5 %. For ileocolonic malignancy, FC ≥1000 µg/g showed 100 % sensitivity and specificity (p = 0.0009). CONCLUSION: CRC screening in pwCF is critical given the high prevalence of neoplasia. Alternative non-invasive screening may support risk stratification among individuals with comorbidities, or reluctance, though performance could be influenced by CFTR modulator therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, 2050, Australia; University of New South Wales, School of Clinical Medicine, Discipline of Paediatrics & Child…
- Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, 2050, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, 2050, Australia.
- University of New South Wales, School of Clinical Medicine, Discipline of Paediatrics & Child Health, UNSW Medicine and Health, Randwick Clinical Campus, Sydney, NSW, 2052, Australia.
- University of New South Wales, School of Clinical Medicine, Discipline of Paediatrics & Child Health, UNSW Medicine and Health, Randwick Clinical Campus, Sydney, NSW, 2052, Australia; Department of Gastroenterology, Syd…
- Sydney Medical School, University of Sydney, Camperdown, NSW, 2050, Australia; Department of Drug Health Services, Royal Prince Alfred Hospital, and the Department of Medicine. Missenden Road, Camperdown, NSW, 2050, Aus…
- AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW, 2050, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, 2050, Australia; Department of D…
Förderung
- Cystic Fibrosis Foundation
- National Health and Medical Research Council
- Australian Cystic Fibrosis Research Trust
Zitieren
APA
Taylor, N. A., Sivam, S., van Dorst, J., Coffey, M. J., Visser, S., Haber, P., Volovets, A., & Ooi, C. Y. (2026). Stool and symptom testing in ColoREctal Evaluation for Neoplasia in Cystic Fibrosis (SCREEN-CF). Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.09.008
Vancouver
Taylor NA, Sivam S, van Dorst J, Coffey MJ, Visser S, Haber P, et al. Stool and symptom testing in ColoREctal Evaluation for Neoplasia in Cystic Fibrosis (SCREEN-CF). Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2025.09.008
BibTeX
@article{Taylor2026,
author = {Taylor, Nicole A and Sivam, Sheila and van Dorst, Josie and Coffey, Michael J and Visser, Simone and Haber, Paul and Volovets, Anastasia and Ooi, Chee Y},
title = {Stool and symptom testing in ColoREctal Evaluation for Neoplasia in Cystic Fibrosis (SCREEN-CF)},
journal = {Journal of Cystic Fibrosis},
year = {2026},
doi = {10.1016/j.jcf.2025.09.008}
}
EUVIMED